Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - Deferred ChargesCost of RevenueLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

BioXcel Therapeutics (BTAI) Accumulated Depreciation & Amortization (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Accumulated Depreciation & Amortization data on record, last reported at $1.6 million in Q1 2025.

  • For Q1 2025, Accumulated Depreciation & Amortization rose 24.15% year-over-year to $1.6 million; the TTM value through Mar 2025 reached $1.6 million, up 24.15%, while the annual FY2024 figure was $1.5 million, 25.9% up from the prior year.
  • Accumulated Depreciation & Amortization reached $1.6 million in Q1 2025 per BTAI's latest filing, up from $1.5 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $1.6 million in Q1 2025 and bottomed at $885000.0 in Q4 2022.
  • Average Accumulated Depreciation & Amortization over 4 years is $1.2 million, with a median of $1.2 million recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation & Amortization: surged 34.8% in 2023, then increased 24.15% in 2025.
  • A 4-year view of Accumulated Depreciation & Amortization shows it stood at $885000.0 in 2022, then soared by 34.8% to $1.2 million in 2023, then increased by 25.9% to $1.5 million in 2024, then grew by 5.06% to $1.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $1.6 million in Q1 2025, $1.5 million in Q4 2024, and $1.3 million in Q1 2024.